Physician profile
Matthew Jacobson
NPI 1346385507
$10,082.12
in general payments reported to CMS, 2019-2025
46 companies · $2,127 in 2025
The $2,127 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $450 · 2021: $685 · 2022: $1,546 · 2023: $1,992 · 2024: $2,078 · 2025: $2,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,190 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,189.92 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,524.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,356.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,258.23 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,013.37 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $689.90 | 2019-2025 | |
| Lilly USA, LLC | $562.30 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $488.73 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $415.28 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.47 | 2019-2025 | Jardiance |
| Amgen INC. | $234.58 | 2019-2025 | Otezla, Repatha, Otezla |
| Amarin Pharma, INC. | $184.88 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $183.09 | 2019-2025 | Verquvo, Gardasil 9, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.12 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $148.55 | 2023-2025 | |
| Exact Sciences Corporation | $132.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.